GRAIL, Inc. (NASDAQ:GRAL) Stock Has Consensus Target Price of $119.80 According to Analysts

GRAIL, Inc. (NASDAQ:GRAL) has been given a consensus recommendation of “Hold” by the twelve brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $119.80.

Several brokerages recently commented on GRAL. Royal Bank Of Canada assumed coverage on shares of GRAIL in a research note on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 price objective for the company. UBS Group boosted their target price on shares of GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Canaccord Genuity Group upped their price target on shares of GRAIL from $80.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 28th. Robert W. Baird upped their price target on shares of GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday, September 22nd. Finally, Guggenheim increased their price target on GRAIL from $75.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, October 1st.

GRAIL Trading Down 9.7%

Shares of NASDAQ GRAL opened at $143.43 on Tuesday. The company has a market cap of $6.41 billion, a price-to-earnings ratio of -14.71 and a beta of 2.83. GRAIL has a 12 month low of $41.50 and a 12 month high of $166.48. The stock has a 50-day moving average price of $112.02 and a two-hundred day moving average price of $78.55.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.66) by $0.10. The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. On average, sell-side analysts predict that GRAIL will post -10.07 earnings per share for the current year.

Insider Buying and Selling

In other GRAIL news, CFO Aaron Freidin sold 23,619 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $3,457,585.41. Following the completion of the transaction, the chief financial officer directly owned 225,364 shares in the company, valued at approximately $32,991,035.96. This trade represents a 9.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Joshua J. Ofman sold 20,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $136.85, for a total value of $2,737,000.00. Following the completion of the transaction, the chief executive officer owned 342,271 shares of the company’s stock, valued at $46,839,786.35. This represents a 5.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 129,944 shares of company stock worth $14,832,805 in the last 90 days. Insiders own 1.83% of the company’s stock.

Institutional Trading of GRAIL

A number of hedge funds have recently made changes to their positions in GRAL. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of GRAIL during the third quarter valued at $320,000. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of GRAIL by 2.3% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,550 shares of the company’s stock worth $2,459,000 after purchasing an additional 400 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of GRAIL by 21.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,350 shares of the company’s stock worth $1,550,000 after purchasing an additional 2,020 shares during the period. North Star Investment Management Corp. grew its stake in shares of GRAIL by 809.1% in the third quarter. North Star Investment Management Corp. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 267 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in shares of GRAIL in the third quarter worth $6,021,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.